Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF01454 MAGE family PF12440 Melanoma associated antigen family N terminal |
Function |
Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. |
Biological Process |
GO:0010466 negative regulation of peptidase activity GO:0010951 negative regulation of endopeptidase activity GO:0010955 negative regulation of protein processing GO:0016485 protein processing GO:0034976 response to endoplasmic reticulum stress GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0045861 negative regulation of proteolysis GO:0051346 negative regulation of hydrolase activity GO:0051604 protein maturation GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress GO:0070613 regulation of protein processing GO:0097193 intrinsic apoptotic signaling pathway GO:1902235 regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902532 negative regulation of intracellular signal transduction GO:1903317 regulation of protein maturation GO:1903318 negative regulation of protein maturation GO:1903573 negative regulation of response to endoplasmic reticulum stress GO:2000116 regulation of cysteine-type endopeptidase activity GO:2000117 negative regulation of cysteine-type endopeptidase activity GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001242 regulation of intrinsic apoptotic signaling pathway GO:2001243 negative regulation of intrinsic apoptotic signaling pathway |
Molecular Function |
GO:0002020 protease binding GO:0089720 caspase binding |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MAGEA3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between MAGEA3 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MAGEA3 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MAGEA3 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MAGEA3 in various data sets.
|
Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAGEA3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAGEA3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAGEA3. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAGEA3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MAGEA3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MAGEA3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MAGEA3 |
Name | melanoma antigen family A3 |
Aliases | HYPD; HIP8; MGC14613; CT1.3; melanoma-associated antigen 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis ant ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MAGEA3 collected from DrugBank database. |
There is no record. |